Lunesta (Eszopiclone) for Adults 65 and Older: What Geriatric Patients and Caregivers Need to Know About Transitioning to Adult Care

Why Eszopiclone Dose and Safety Standards Differ in Adults 65 and Older

Older adults metabolize eszopiclone more slowly. The FDA prescribing information for Lunesta states that the maximum recommended starting dose in elderly patients is 1 mg at bedtime, compared to 1 to 3 mg in younger adults, because plasma concentrations are meaningfully higher after the same nominal dose. This pharmacokinetic difference is not trivial. A 1 mg dose in a 70-year-old can produce blood levels equivalent to a 2 mg dose in a 45-year-old, depending on hepatic blood flow and CYP3A4 activity.

How Aging Changes Eszopiclone Pharmacokinetics

Hepatic first-pass metabolism declines with age, and total body water decreases while adipose tissue increases. Both factors affect lipophilic compounds like eszopiclone. The half-life extends from roughly 6 hours in younger adults to approximately 9 hours in adults over 65, raising the probability of residual sedation the following morning.

The FDA label for Lunesta specifies that "the recommended dose is 1 mg immediately before bedtime" for elderly or debilitated patients, with a maximum of 2 mg only if 1 mg is insufficient and tolerated. [1] This is a hard ceiling, not a suggestion.

Beers Criteria Classification

The American Geriatrics Society (AGS) 2023 Beers Criteria explicitly lists all nonbenzodiazepine receptor agonists, including eszopiclone, zolpidem, and zaleplon, as potentially inappropriate medications in older adults. [2] The criteria cite increased risk of delirium, falls, fractures, and motor vehicle accidents. The specific language in the 2023 update notes these agents should be avoided or used only if other treatments have failed, and only at the lowest effective dose for the shortest possible duration.

Falls and Fracture Risk: The Numbers

A 2014 analysis published in the BMJ (N=34,727) found that hypnotic use in older adults was associated with a 4-fold increase in mortality risk over 2.5 years compared with non-use, though causality is difficult to isolate from severity of underlying illness. [3] More directly applicable: a case-control study in JAMA Internal Medicine demonstrated that zolpidem use in patients over 65 was associated with an odds ratio of 2.55 for hip fracture within the first 2 weeks of use. [4] Eszopiclone shares the same mechanism and comparable pharmacodynamic profile, making extrapolation clinically reasonable.

Transitioning Geriatric Patients from Inpatient or Specialty Care to Adult Outpatient Settings

The transition from hospital, rehabilitation facility, or specialist care back to a primary care or telehealth outpatient environment is one of the highest-risk periods for medication error in older adults. For sedative-hypnotics specifically, two failure modes dominate: dose continuation at the inpatient level (typically higher) and medication duplication when a receiving provider prescribes a new sleep agent without recognizing an existing prescription.

Medication Reconciliation at Every Handoff

The Joint Commission's National Patient Safety Goal NPSG.03.06.01 requires complete medication reconciliation at every transition point. [5] Yet a 2019 study in Annals of Internal Medicine found that 23% of older adults experienced at least one medication discrepancy at discharge, with sedative-hypnotics among the most commonly duplicated drug classes.

For eszopiclone specifically, outpatient adult care providers receiving a geriatric patient should confirm:

1. The exact dose being taken (1 mg vs. 2 mg vs. 3 mg).
2. Duration of current use (greater than 4 weeks raises deprescribing candidacy).
3. Whether the drug was initiated in the hospital or predates admission.
4. Any concurrent CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir) that dramatically increase eszopiclone plasma levels.

What the Receiving Clinician Should Do on Day One

The first outpatient visit after care transition should include a full sleep and sedative review. If eszopiclone was started in a hospital or rehab setting for acute insomnia, the outpatient clinician should plan to taper rather than continue indefinitely. The standard taper in clinical practice is a 25 to 50% dose reduction every 1 to 2 weeks. For a patient on 2 mg, a reasonable schedule is 2 mg for 1 week, then 1 mg for 1 to 2 weeks, then 0.5 mg (tablet splitting, if feasible) before discontinuation.

Rebound insomnia typically peaks at 1 to 2 nights after the final dose and resolves within 1 to 2 weeks. Patients should be told this explicitly to prevent unilateral reinstatement of the medication.

Red Flags That Require Immediate Dose Review

• Any fall occurring within 8 hours of taking eszopiclone.
• Patient reporting that the drug "doesn't work anymore" (tolerance) and self-escalating.
• New prescription of another CNS depressant (opioid, benzodiazepine, antihistamine).
• Cognitive complaints or new delirium after starting eszopiclone.
• Severe hepatic impairment diagnosis that was absent at the time of initial prescription.

Eszopiclone Drug Interactions That Are Especially Relevant in Geriatric Patients

Older adults typically take more medications. The average Medicare beneficiary takes 4 to 5 prescription drugs daily, and many take 10 or more. This polypharmacy backdrop makes drug interactions a primary safety concern with any sedative-hypnotic.

CYP3A4 Inhibitors

Eszopiclone is metabolized almost entirely via CYP3A4. Co-administration with ketoconazole 400 mg (a potent CYP3A4 inhibitor) increased eszopiclone Cmax by 1.4-fold and AUC by 2.2-fold in a pharmacokinetic study cited in the FDA label. [1] In a geriatric patient already experiencing prolonged half-life, doubling the AUC can produce sedation lasting well into the following day.

Common CYP3A4 inhibitors encountered in geriatric care include:

• Clarithromycin (respiratory infections)
• Diltiazem and verapamil (cardiac conditions)
• Fluconazole (fungal infections, though less potent than ketoconazole)
• Ritonavir-boosted HIV regimens

If a geriatric patient on eszopiclone 1 mg begins a 5-day course of clarithromycin, the clinician should consider holding eszopiclone during that course or reducing to the lowest possible dose.

CNS Depressant Combinations

The FDA's 2019 Boxed Warning on opioid and CNS depressant combinations applies to eszopiclone. [6] The warning requires prescribers to avoid concurrent use of opioids and benzodiazepine-class drugs (including Z-drugs) "except in patients for whom alternative treatment options are inadequate." If co-prescription is necessary, the lowest effective doses for the shortest duration are required.

In geriatric patients, many of whom take low-dose opioids for chronic pain, this interaction is a direct clinical concern, not a theoretical one.

Alcohol

Eszopiclone's pharmacodynamic effects are additive with ethanol. The FDA label explicitly states that patients should not drink alcohol while taking Lunesta. In outpatient geriatric care, alcohol use may not be routinely screened. The CAGE questionnaire or AUDIT-C screen takes under 2 minutes and should be part of any initial post-transition visit for a patient receiving a sedative-hypnotic.

Evidence-Based Alternatives to Eszopiclone in Adults 65 and Older

The first-line treatment for chronic insomnia disorder in any age group, including older adults, is Cognitive Behavioral Therapy for Insomnia (CBT-I), not pharmacotherapy. The American College of Physicians (ACP) published a strong recommendation for CBT-I as initial therapy in their 2016 clinical guideline, reaffirmed with supporting evidence from multiple systematic reviews. [7]

CBT-I Outcomes in Older Adults

A meta-analysis published in Sleep Medicine Reviews (2020) found that CBT-I produced clinically meaningful improvements in sleep onset latency, wake after sleep onset, and sleep efficiency in adults over 60, with effect sizes comparable to those seen in younger adults. [8] The effects of CBT-I are also more durable than pharmacotherapy: benefits are generally maintained at 6 to 12 month follow-up without continued intervention.

For older adults who cannot access in-person CBT-I, digital CBT-I platforms (dCBT-I) have demonstrated efficacy. The Sleepio trial, a randomized controlled trial (N=1,711), found that the digital CBT-I program produced a 50% reduction in insomnia severity index scores compared with control. [9]

Lower-Risk Pharmacologic Options

If medication is required after CBT-I fails or while awaiting access to behavioral therapy, clinicians should consider:

Doxepin 3 to 6 mg (Silenor): FDA-approved for sleep maintenance insomnia. At doses of 3 to 6 mg, doxepin acts primarily as an H1 receptor antagonist rather than a tricyclic antidepressant. A randomized controlled trial in adults 65 to 85 years (N=254) showed that doxepin 3 mg and 6 mg significantly improved sleep maintenance vs. Placebo with no significant next-morning residual effects. [10]

Melatonin receptor agonists: Ramelteon 8 mg has a favorable safety profile in older adults. It does not appear on the Beers Criteria as a drug to avoid and carries no abuse potential. Evidence for sleep maintenance is modest, but it may benefit older patients with circadian phase issues.

Suvorexant (Belsomra): An orexin receptor antagonist approved for sleep-onset and sleep-maintenance insomnia. The 2022 AGS Beers Criteria does not list suvorexant as a drug to avoid in older adults, though it notes that evidence in this population is limited compared to younger adults. Falls risk with suvorexant appears lower than with Z-drugs in available data, though direct head-to-head trials in geriatric populations are lacking.

Agents to Avoid

OTC antihistamines (diphenhydramine, doxylamine) are widely used by older adults for sleep but are explicitly listed in the Beers Criteria as drugs to avoid in this population due to anticholinergic effects, which include urinary retention, constipation, confusion, and increased fall risk. [2] A patient transitioning from a hospital setting may have used diphenhydramine while admitted. If so, this should be explicitly discontinued at the outpatient transition.

Deprescribing Eszopiclone in Geriatric Patients: A Structured Approach

Deprescribing Z-drugs in older adults is recommended by multiple guidelines but is often deferred because both patients and clinicians fear rebound insomnia. The evidence supports structured tapering as effective and well-tolerated.

When to Initiate a Deprescribing Conversation

The Canadian Deprescribing Network and the AGS both recommend initiating a conversation about sedative-hypnotic discontinuation when:

• Use has exceeded 4 weeks.
• The original indication (acute insomnia, hospitalization-related sleep disruption) has resolved.
• The patient has had a fall or reports excessive sedation.
• Cognitive changes have been noted.

A direct, non-alarmist framing works best. Phrasing like "We'd like to try reducing this medication over a few weeks because your sleep has been more stable, and it will likely be easier on your body long-term" tends to improve patient acceptance compared to abrupt cessation recommendations.

The Taper Protocol

Published taper protocols from the Canadian Family Physician (2018) recommend a step-wise 25% dose reduction every 2 weeks, with CBT-I or sleep hygiene support initiated simultaneously. [11] For a patient on eszopiclone 2 mg:

• Weeks 1 to 2: eszopiclone 2 mg
• Weeks 3 to 4: eszopiclone 1 mg
• Weeks 5 to 6: eszopiclone 1 mg every other night (or 0.5 mg nightly if tablet splitting is possible)
• Week 7 onward: discontinue

Patients should be told that mild rebound insomnia (1 to 3 nights of worse sleep) is normal and expected. Providing written sleep hygiene instructions at the time of taper initiation significantly improves completion rates.

Monitoring During the Taper

Weekly brief check-ins, even by phone or secure message, reduce dropout rates during sedative tapering. The Insomnia Severity Index (ISI), a validated 7-item questionnaire, can be administered at each touchpoint to track progress. An ISI score below 8 is considered within normal limits.

Special Populations Within the Geriatric Group

Adults Over 80

Patients over 80 are substantially underrepresented in clinical trials of eszopiclone. The key Phase III trial that supported FDA approval enrolled adults with a mean age of approximately 44 years. Extrapolating efficacy and safety data to octogenarians introduces real uncertainty. In practice, clinicians treating adults over 80 should apply an even more conservative threshold: the 1 mg maximum dose is a ceiling, and for some patients, 0.5 mg (achieved by splitting the 1 mg tablet) may be a more appropriate starting point.

Patients With Dementia

Eszopiclone should generally be avoided in patients with any degree of dementia. GABA-A agonists can worsen confusion, increase agitation, and precipitate paradoxical excitation in this population. If sleep disruption in a dementia patient is severe, a geriatric psychiatry consultation and a behavioral management approach should precede any pharmacologic trial.

Patients With Hepatic Impairment

The FDA label specifies that in patients with severe hepatic impairment, eszopiclone exposure is doubled due to reduced first-pass metabolism. [1] A maximum dose of 1 mg applies regardless of age, and in geriatric patients with hepatic impairment, even 1 mg may produce disproportionate sedation. Liver function should be reviewed at every transition point.

The Role of Telehealth Platforms in Geriatric Eszopiclone Management

Telehealth prescribing of controlled substances expanded significantly after the COVID-19 public health emergency, and eszopiclone (a Schedule IV controlled substance) has been accessible through telehealth platforms during this period. The DEA's proposed 2023 telemedicine rules would require at least one in-person visit before prescribing certain controlled substances, including Schedule IV agents, for new patients. [12]

For geriatric patients receiving eszopiclone through a telehealth adult care provider, the transition from emergency-era prescribing to the post-PHE environment may itself constitute a care transition. Providers should document:

• Whether the initial prescribing encounter was in-person or virtual.
• Current dose and duration of use.
• Patient's awareness of and consent to tapering if the drug is no longer prescribable in the new regulatory context.

Geriatric patients, who may have limited transportation or mobility, are more dependent on telehealth access than younger populations. Abrupt discontinuation of eszopiclone without a supported taper plan poses real clinical risk. Providers should plan proactively rather than waiting for a regulatory deadline to force the issue.